Edwards Lifesciences Corporation $EW Shares Bought by NorthRock Partners LLC

NorthRock Partners LLC raised its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 13.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,705 shares of the medical research company’s stock after purchasing an additional 2,650 shares during the period. NorthRock Partners LLC’s holdings in Edwards Lifesciences were worth $1,776,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. SouthState Corp purchased a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $27,000. Global X Japan Co. Ltd. lifted its position in shares of Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 216 shares in the last quarter. Tradewinds Capital Management LLC lifted its position in shares of Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 205 shares in the last quarter. Finally, Rossby Financial LCC purchased a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of analyst reports. Evercore ISI set a $88.00 price objective on Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Stifel Nicolaus set a $85.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Monday, September 22nd. Finally, William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $87.06.

Edwards Lifesciences Stock Down 1.4%

Edwards Lifesciences stock opened at $72.94 on Tuesday. The company has a market capitalization of $42.82 billion, a P/E ratio of 10.49, a PEG ratio of 3.55 and a beta of 1.05. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $83.00. The stock has a 50-day simple moving average of $77.95 and a 200-day simple moving average of $76.18. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the business posted $0.70 EPS. Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.